Dan Liu

Dan Liu

Auto-generated profile, based on publicly available information

Dan Liu

State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2025 in Science Advances
Verified
Journal Article
Open access
YLYaohao Li
Yaohao Li
WLWenqiang Liu
Wenqiang Liu
RWRuihan Wang
Ruihan Wang
DLDan Liu
Dan Liu
XLXin Li
Xin Li
ZTZhongping Tan
Zhongping Tan
Protein and peptide aggregation poses substantial challenges in disease pathology and therapeutic development. While natural glycosylation may mitigate aggregation, its efficacy and underlying mechanisms remain poorly understood due to limited access to homogeneous samples with complex glycans. This study addresses these knowledge gaps by investigating the natural glycosylation of islet amyloid polypeptide (IAPP), a peptide with therapeutic potential for type 2 diabetes but problematic aggregation. An optimized chemical synthesis enabled preparation of diverse IAPP glycoforms with complex glycan structures, allowing systematic evaluation of their effects on aggregation, cytotoxicity, and solubility. Sialylated glycans at Thr 30 completely inhibited IAPP aggregation, eliminated cytotoxicity toward pancreatic β cells, and enhanced solubility by up to 280-fold. Replica exchange molecular dynamics simulations revealed that glycosylation impedes adoption of a four-stranded β-sheet conformation in IAPP dimers. These findings advance the understanding of the role of natural glycosylation in aggregation and highlight its potential as an evolutionarily inspired strategy to enhance the therapeutic utility of IAPP.